SCHEMBL722294

SCHEMBL722294

COCc1cc(C)on1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20232092 0.83 MAPT (0.36)
SCHEMBL20232097 0.81 MAPT (0.36)
SCHEMBL1715595 0.81
SCHEMBL722293 0.81
SCHEMBL20232093 0.80 HDAC3 (0.35)
SCHEMBL20232091 0.80 HDAC3 (0.38)
Hydrochloric Acid SCHEMBL3170086 0.79 MAPT (0.39)
SCHEMBL9971015 0.79 NPC1 (0.40)
SCHEMBL20232102 0.79 MAPT (0.39)
SCHEMBL20232101 0.79 HDAC3 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598154-B2 Pyridyl-amine fused azadecalin modulators CORCEPT THERAPEUTICS, INC. (US) 2013-12-03 US claimed
EP-2609097-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS Corcept Therapeutics, Inc. (US) 2013-07-03 EP claimed
US-20120220565-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-08-30 US claimed
WO-2012027702-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-03-01 WO claimed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-11891381-B2 Compounds for the treatment of glycogen storage disorders HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2024-02-06 US disclosed
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use YALE UNIVERSITY (US) 2023-12-05 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 EP disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-7169817-B2 Bis-aromatic alkanols IRM LLC (BM) 2007-01-30 US disclosed
US-7169817-B2 Bis-aromatic alkanols IRM LLC (BM) 2007-01-30 US disclosed
WO-2006098683-A1 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-09-21 WO disclosed
EP-0836604-A1 NOVEL SUBSTITUTED AZABICYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1998-04-22 EP disclosed
US-5622953-A DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG BASF AKTIENGESELLSCHAFT (DE) 1997-04-22 US disclosed
WO-1997001558-A1 NOVEL SUBSTITUTED AZABICYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1997-01-16 WO disclosed